This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Study Type
OBSERVATIONAL
Enrollment
500
Changes in ctDNA from baseline, on-treatment and post-treatment blood samples.
Assess ctDNA kinetics using ctDNA clearance factors such as time to clearance, best overall clearance rate, best confirmed clearance, and time to ctDNA recurrence and correlate with standard of care therapy real-world outcomes such as overall survival, progression-free survival, time to next treatment, and time to treatment discontinuation.
Time frame: 5 years
Generation of DNA, RNA, immune and other multiomic datasets.
Use blood and tissue based next generation sequencing to uncover biomarkers that may predict outcomes, identify markers related to disease, identify markers related to mechanism of drug action, and inform future research.
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alabama Oncology
Birmingham, Alabama, United States
RECRUITINGPIH Health Whittier Hospital & PIH Health Physicians
Whittier, California, United States
RECRUITINGEastern CT and Hematology and Oncology Associates
Norwich, Connecticut, United States
RECRUITINGCancer Specialists of North Florida
Jacksonville, Florida, United States
RECRUITINGMorehouse
Atlanta, Georgia, United States
RECRUITINGPiedmont Healthcare
Atlanta, Georgia, United States
RECRUITINGSouthern Illinois Healthcare
Carterville, Illinois, United States
RECRUITINGHope and Healing Cancer Services
Hinsdale, Illinois, United States
RECRUITINGCancer Care Specialists of Illinois
O'Fallon, Illinois, United States
RECRUITINGIllinois Cancer Care
Peoria, Illinois, United States
RECRUITING...and 22 more locations